According to an MSU (Michigan State University) scientist, innovative research in a genetic mutation role in breast cancer can open new options for treatment in lung cancer. Eran Andrechek—Physiology Professor at College of Human Medicine—said, “We sorted the whole genome of breast cancer samples and discovered a compelling mutation that previously was not recognized as significant in lung cancer. This mutation has comprehensible potential to recognize lung cancer patients who must be receiving specific therapy that is already sanctioned by the U.S. FDA (Food and Drug Administration).” The research was issued in the journal Nature Communications.
By using computational analysis of sequenced genes and lab mice, Andrechek and his colleagues studied that a mutation is present, but it seems not that significant, in breast cancer turns out to slow up growth of some human lung cancer tumors. He said around 5% of lung cancer cases have this mutation. That sums out to approximately 11,000 people in the U.S. alone who can gain more time from the most fierce of major cancers. He warned, “It is not a cure. It has the prospective to prolong life span and amplify the patients’ quality of life.” Andrechek along with his team discovered several genes that were increased in mice and in human breast cancer and by using CRISPR gene-editing technology, was capable to block cancer cells from progression.
Recently, MSU was in the news as its study stated that vitamin D might not help the heart condition. Whilst past research has indicated an association amid low levels of vitamin D in the blood and an amplified peril of cardiovascular events, the latest study has discovered that taking vitamin D supplements did not decrease that risk. The large-scale research was published in the Journal of the American Medical Association Cardiology and revealed that vitamin D supplements did not lessen the incidence of strokes, heart attacks, or other major adverse cardiovascular incidents.